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Background: Prolactin (PRL) is a hormone synthesized in both the pituitary gland and extrapituitary sites. It has
been associated with the occurrence of neoplasms and, more recently, with central nervous system (CNS)
neoplasms. The aim of this study was to evaluate prolactin expression in primary central nervous system tumors
through quantitative real-time PCR and immunohistochemistry (IH).
Results: Patient mean age was 49.1 years (SD 15.43), and females accounted for 70% of the sample. The most
frequent subtype of histological tumor was meningioma (61.5%), followed by glioblastoma (22.9%). Twenty cases
(28.6%) showed prolactin expression by immunohistochemistry, most of them females (18 cases, 90%). Quantitative
real-time PCR did not show any prolactin expression.
Conclusions: Despite the presence of prolactin expression by IH, the lack of its expression by quantitative real-time
PCR indicates that its presence in primary tumors in CNS is not a reflex of local production.
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PRL was initially associated with mammary development
and lactation. However, more than 300 biological func-
tions have been attributed to this hormone [1]. The
human PRL gene is located on chromosome 6 and its
expression is not limited to the pituitary gland, occur-
ring also in such extrapituitary sites as endometrium, de-
cidua, myometrium, T lymphocytes, leukocytes, brain,
prostate, skin and adipose tissue [2,3]. The gene tran-
scription is further regulated by two independent pro-
moters: a proximal pituitary PRL promoter and a distal
extrapituitary PRL promoter [4].
Recent studies have suggested an association of PRL
with tumor proliferation, evidencing the hormone as an
antiapoptotic or mitogenic factor [1]. Studies showed that
PRL extends the lobular-alveolar cells survival on the lac-
tating mammary gland, inhibiting apoptosis and stimulat-
ing the proliferation of many cell lines of breast cancer [5].
In vivo studies showed that high levels of PRL accelerated
the emergence of spontaneous mammary tumors [6] and* Correspondence: grazi_mendes@hotmail.com
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distribution, and reproduction in any mediumcould act as an anti-cytotoxic factor in breast cancer cells,
contributing to drug resistance [7]. PRL is also involved in
prostate tumor growth, acting as a survival factor for epi-
thelial cells, and PRL expression was correlated with
tumor differentiation degree [8-10]. In addition, hyperpro-
lactinemia was associated with a worse prognosis in
patients with colon and rectum cancer [11].
Regarding the CNS, there are studies showing the
presence of hyperprolactinemia, intracellular PRL and
PRL receptor (PRL-R) in different types of CNS tumors
[12,13], and intracellular PRL and serum PRL were asso-
ciated with a tendency of increased vascular density and
significant increase of cell proliferation markers Ki-67
and Mcm-2, suggesting that PRL may play a role in the
development of these tumors [14].
The purpose of this study was to assess PRL expres-
sion in primary CNS tumors by real-time PCR and to
correlate these findings with immunohistochemical hor-
mone detection, contributing to a better understanding
of the interrelationship between PRL and CNS tumors.
Results
The study included 70 patients: 49 (70%) females and 21
(30%) males. Their mean age was 49.1 years (SD 15.43).d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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was statistically significantly different (p = 0.046) from
that of the group with negative IH (46.78 years).
As for pathological diagnosis, the most frequent histo-
logical subtype was meningioma (43 cases, 61.5%), followed
by glioblastoma (16 cases, 22.9%), astrocytoma (5 cases,
7.2%) oligoastrocytoma and anaplastic oligodendroglioma
(2 cases each, 2.8%), anaplastic ependymoma (1 case,
1.4%), and glioma (1 case, 1.4%). Regarding tumor location,
43 cases (61.5%) were located in the meninges, 26
cases (37.1%) were supratentorial, and 1 case (1.4%)
infratentorial.
Regarding IH expression of intracellular PRL, 20 cases
were positive, representing 28.6% of the sample with a
predominance of females (18 cases, 90%). Of the positive
cases, 15 were meningiomas (transitional meningioma, 8
cases, 40%; meningeal meningioma, 5 cases, 25%; psam-
momatous meningioma, 1 case, 5%; secretory meningi-
oma, 1 case, 5%), one was oligoastrocytoma (5%) and 4
were glioblastomas (20%) (Table 1). See Figure 1 and 2.
Statistical significance was obtained by relating gender
(18 females versus 2 males) to IH PRL positivity (p =
0.043). There was no statistically significant relationship
of IH PRL positivity with age (< 40 and ≥ 40 years),
pathological diagnosis, and tumor location (Table 2).Table 1 Sex, age, histological diagnosis, location and grade o
immunohistochemistry for PRL
Case Sex Age (years) Histolog
1 F 74 Transitio
2 F 51 Glioblast
3 F 64 Transitio
4 F 53 Meninge
5 F 69 Meninge
6 F 49 Psammo
7 F 60 Transitio
8 F 84 Glioblast
9 F 57 Transitio
10 F 55 Meninge
11 F 52 Meninge
12 F 37 Glioblast
13 F 47 Secretor
14 F 34 Transitio
15 F 59 Meninge
16 F 63 Glioblast
17 F 37 Transitio
18 M 62 Transitio
19 M 34 Oligoast
20 F 57 Transitio
Sex: F=females; M=males; PRL=prolactin.Quantitative real-time PCR failed to show any PRL ex-
pression in both normal CNS tissue and CNS tumor
samples.
Discussion
The current series is characterized by primary CNS
tumor-bearing patients whose ages were similar to those
of patients in other studies [15,16]. Meningiomas pre-
vailed in association with female predominance [17].
Regarding location, most meningiomas in our sample
occurred at different locations as compared to most
tumors described in the literature [18].
In our study, 28.6% of the sample presented positive
IH to PRL. Unlike Abech and colleagues’ findings [14],
PRL was positive in older patients in our series. In 1999,
positive IH for PRL was described in a patient with
gangliocytoma [19].
Hyperprolactinemia and presence of intracellular PRL
and PRL-R have been detected by immunohistochemis-
try in different types of CNS tumors. Cicarelli and col-
leagues [12] found hyperprolactinemia and presence of
PRL-R in 27.2% and 45.4% of meningiomas and 61.5%
and 69.2% of schwannomas, without correlation of
hyperprolactinemia with PRL-R. Leães and colleagues
[13] identified hyperprolactinemia in 30.5%, presence off primary CNS tumors in patients with positive
ical diagnosis Location Grade
nal meningioma Meninge I
oma Supratentorial IV
nal meningioma Meninge I
al meningioma Meninge I
al meningioma Meninge I
matous meningioma Meninge I
nal meningioma Meninge I
oma Supratentorial IV
nal meningioma Meninge I
al meningioma Meninge I
al meningioma Meninge I
oma Supratentorial IV
y meningioma Meninge I
nal meningioma Meninge I
al meningioma Meninge I
oma Supratentorial IV
nal meningioma Meninge I
nal meningioma Meninge II
rocytoma Supratentorial II
nal meningioma Meninge I
Table 2 Rates of positivity for PRL by
immunohistochemistry
PRL IH (+)
Variable n nº % p
Age, years 0.386[1]
<40 21 4 19.0
≥40 49 16 32.7
Sex 0.043[1]
males 21 2 9.5
females 49 18 36.7
Histological type 0.461[2]
Meningioma 43 15 34.9
Glioblastoma 16 4 25.0
Astrocytoma 5 0 0.0
Others 6 1 16.7
Location 0.356[2]
Meninges 43 15 34.9
Supratentorial 26 5 19.2
Infratentorial 1 0 0.0
PRL: prolactin; IH: immunohistochemistry; [1]: Chi-Square Test (Yates); [2]:
Fisher’s exact test; nº: number of cases.
Figure 1 Meningioma showing PRL immunopositivity in
meningothelial cells (400x).
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with positive correlation of serum PRL with presence of
intracellular PRL. A recent study by Abech and collea-
gues [14] revealed presence of intracellular PRL in 45.6%
of neuroepithelial tumors and meninges and elevated
serum PRL in 33.9% of the cases. Therefore, our findings
of positive intracellular PRL are similar to the those of
the literature. The meaning of intracellular presence of
PRL may vary according to the malignant potentials of
the tumors, and there is no data in the current literature
on the possible causes for the presence of positive PRL
immunohistochemistry in different types of CNS tumors.
However, in gliomas of different grades, Scott and col-
leagues [20] found a significant increase in the expres-
sion of Ki-67, Mcm-2 and cyclin A and B1 as tumor
grade increased, and it is speculated that PRL, like the
above-mentioned proteins, may be related to more ag-
gressive tumors [1]. Ducret and colleagues [21] demon-
strated increased intracellular calcium in glioblastoma
cells induced by the presence of PRL, increased thymi-
dine incorporation, cell growth and half-life. RegardingFigure 2 Glioblastoma with PRL immunopositivity (400x).meningiomas, Jimenez-Hakim and colleagues [22]
demonstrated that PRL concentrations stimulated the
growth of meningiomas significantly.
A single report utilizing conventional PCR detected
PRL mRNA expression in the human hypothalamus, pi-
tuitary and cerebellum [23]. In studies with rats, PRL
mRNA was detected in various degrees in the hypothal-
amus, cerebellum, caudate, brain stem, amygdala, thal-
amus, hippocampus and cortex [24,25]. In this study, no
expression of PRL was identified in the pool of 9 sam-
ples of CNS peritumoral tissue (gray and white matter
and meningothelial tissue) through quantitative real-
time PCR. Real-time PCR is the most powerful tool for
quantitative nucleic acids analysis. It is widely consid-
ered as the gold standard for nucleic acid quantification
and has become the method of choice for the detection
of mRNA because of its unparalleled amplification and
precision capability [26-29]. Sample of prolactinoma was
used as positive control, demonstrating that real-time
PCR is able to identify PRL expression. It removes the
possibility that the technique was not sensitive enough
to detect PRL and to corroborate immunohistochemical
findings. In general, polyclonal antibodies have high af-
finity and wide reactivity, becoming more sensible as
compared with monoclonal antibodies because they are
more likely to identify multiple epitopes of the target
protein. However, their specificity is lower as compared
to monoclonal antibodies, being more susceptible to
cross-reactivity with other antigens [30]. PCR methods
generally have a higher sensitivity and specificity than
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results of immunohistochemistry and PCR methods can
be low [31-33]. Real time -PCR is the most sensitive
method for the detection and quantification of mRNA,
especially for low abundance specimens, like RNAs,
cells and tissues [27,34]. Real time-PCR assays are
10.000 to 100.000-fold more sensitive than RNase pro-
tection assays, 1000-fold more sensitive than dot blot
hybridization, detecting a single copy of a specific
transcript and is a method with lower variation, usually
between 0 and 5% for TaqMan probes [27-29,34,35].
The real time -PCR technique, specially with TaqMan
probes, is the best option when analyzing gene with low
expression level, from limited samples once high sensi-
tivity and accuracy are needed [27,36]. There is no data
in the current literature about PRL gene expression by
quantitative real-time PCR in normal samples of the
CNS. To the best of our knowledge, there are no studies
analyzing PRL gene expression in different types of CNS
tumors either by conventional PCR or by quantitative
real-time PCR. Therefore, the absence of PRL expression
by quantitative real-time PCR in human samples of dif-
ferent types of CNS tumors, the main finding of this
study, is an unprecedented one.
So far, the identification of positive PRL by immuno-
histochemistry suggested possible extrapituitary hor-
mone production, but immunological methods do not
allow to discriminate between locally produced PRL and
PRL that is captured by dependent or independent
mechanism of the PRL-R. The PRL-R is ubiquitously
expressed and its isoforms vary across tissues. The long
isoform is highly expressed in the choroid plexus, mam-
mary gland, pancreas, adrenal, kidney and intestine. In
the brain, with the exception of the choroid plexus, there
is a low expression of PRL-R. PRL-R triggers intracellu-
lar signaling pathways, the best known of which being
the Jak-Stat. In breast cancer cells, PRL activates Jak2,
stimulates phosphorylation of Stat1, Stat3 and Stat5 and
induces cell proliferation [37,38]. In breast cancer cells
and Nb2 cells, PRL stimulates ERK1/2 phosphorylation
in the mitogen-activated protein (MAP) kinase pathway,
which appears to mediate the effects of PRL on cell pro-
liferation [39,40]. The PRL-R facilitates the action of
members of the Src kinase family, activating kinase B
protein and the phosphatidylinositol 3-kinase (PI3 kin-
ase) pathway [41]. The interconnection between the dif-
ferent signaling pathways of PRL can increase the
proliferation, survival, cell migration and invasion of
breast cancer [42] and is responsible for mediating antia-
poptotic and proliferative effects of PRL [43]. The ab-
sence of PRL detection by quantitative real-time PCR
does not favor the hypothesis of local production be-
cause, unlike IH, it is a method that analyses the mRNA
of protein in order to identify local production of PRL.In a study by Abech and colleagues [14], 45.6% of cases
presented positive IH to PRL and 30.6% of cases pre-
sented hyperprolactinemia. In addition, in a study car-
ried out by Leães and colleagues [13], of the total
number of patients with positive IH to intracellular PRL,
27.8% presented hyperprolactinemia, 38.9% were positive
for PRL-R, and 44.4% had neither of the two variables.
Although the available data do not allow us to define the
origin of positive IH PRL in primary tumors of the CNS,
they strongly suggest that it does not reflect local pro-
duction. It is postulated that the presence of PRL in
CNS is due to the transport of pituitary PRL from the
blood by the choroid plexus, with subsequent distribu-
tion via cerebrospinal fluid and taking up by neurons
and glial cells to exert modulatory functions. It is pre-
sumed that the PRL receptor or binding protein in the
choroid plexus functions as a transporter, enabling circu-
lating PRL to gain access to various brain regions
[2,44,45].
Conclusions
Despite the presence of prolactin expression by immu-
nohistochemistry, the lack of its expression by quantita-
tive real-time PCR indicates that its presence in primary
tumors in central nervous system is not a reflex of local
production. Thus, further studies are needed regarding
the origin of this PRL identified with the immunohisto-
chemistry technique and its true role in the pathogenesis
of CNS tumors.
Materials and methods
Design: Cross-sectional observational study.
Subjects
Patients with primary diagnosis of CNS tumor who
underwent neurosurgery at Hospital São José, Complexo
Hospitalar Santa Casa of Porto Alegre, Brazil, from Feb-
ruary 2007 to July 2010 were included in this study.
Informed consent was obtained from all subjects before
participation. Medical records were reviewed to collect
data concerning sex, age, tumor location, and anatomo-
pathological diagnosis. The anatomopathological find-
ings were reviewed by a second pathologist.
The study was conducted in a statistically estimated
sample of 70 patients. The research project was
approved by the Ethics Committee of the institution
(263/09).
Immunohistochemistry
Samples of tumoral tissue were fixed with 10% buffered
formalin and embedded in paraffin. Serial 4 μm sections
were stained with hematoxylin and eosin and subjected to
IH. Polyclonal antihuman antibody (Dako, Carpinteria,
CA, code A0569-1, dilution 1:1000) and Advance™ HRT
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used for detection of intracellular PRL. Endogenous per-
oxidase activity was blocked using two baths of 10 minutes
in 5% hydrogen peroxide (H2O2) 30 V in methanol. Un-
specific proteins were blocked using 1% BSA for 30 min-
utes. Incubation with primary antibody was performed
overnight at 4°C. Incubation with secondary antibody and
tertiary antibody was performed for 40 minutes at room
temperature. The same tissues were used as negative con-
trols, incubated with the same antibodies except the pri-
mary one, which was replaced by BSA. The antigen-
antibody binding was visualized with the DAB chromogen
(diaminobenzidin). Counterstaining was with Harris
hematoxylin; the slides were dehydrated and mounted in
synthetic resin. Human pituitary was used as positive con-
trol. Intracellular PRL positivity was based on presence of
at least 1% of cells with clearly marked cytoplasm [13,46].
Quantitative real-time PCR
CNS tumor fragments were obtained immediately after
surgery, snap-frozen in liquid nitrogen and kept in bio-
freezer at −80°C until RNA extraction. The procedure
for RNA extraction was performed using TriReagent
(Ludwig Biotec, Porto Alegre, RS), according to the
manufacturer’s instructions. RNA was reversely tran-
scribed in a final volume of 21μL using Superscript 1ST
Strand System for RT-PCR (Invitrogen, San Diego, CA),
according to the manufacturer’s instructions. All cDNA
samples were quantified using the Nanodrop 1000,
measuring absorbance at 260 nm and 280 nm. Comple-
mentary DNAs were of good quality when the 260/280
ratio was greater than 1.7. The same procedures were
adopted for the pool of normal peritumoral tissue as well
as the prolactinoma used as positive control.
In order to perform quantitative real-time PCR, all
cDNA samples were diluted to a final concentration of
400 ng/μL and amplified using TaqMan gene expression
Assay (PRL Hs01062137_m1; GAPDH Hs99999905_m1)
and TaqMan Gene Expression Master Mix (4369510)
(Applied Biosystems, Foster City, CA) in a total reaction
volume of 15μL, under the following conditions: initial
denaturation at 50°C for 2 minutes and at 95°C for
10 minutes, followed by 40 cycles at 95°C for 15 seconds
and 60°C for 1 minute. The equipment used was the Ste-
pOnePlus (Applied Biosystems, Foster City, CA). For
relative quantification the 2-ΔΔCT method described by
Livak and Schmittgen [47] was adopted. The GAPDH
gene was used as reference.A pool consisting of 9 sam-
ples of normal peritumoral tissue (gray and white matter
CNS and meningothelial tissue) was used as calibrator
to allow comparison between CNS tumoral and normal
samples. A sample of prolactinoma was used as positive
control and mixed reagents without the presence of
cDNA were used as negative control. The tests withCNS tumor samples were performed in duplicate, and
the GAPDH gene and PRL gene were always tested in
the same assay, avoiding possible differences between
assays. The GAPDH gene was detected in all samples.
The PRL gene was detected in the prolactinoma sample
(positive control) in all assays. In each reaction plate and
for each gene tested, the pool of normal CNS tissue sam-
ples (calibrator) was performed in triplicate, the positive
control (prolactinoma) and negative control in duplicate.
Statistical analyses
Age-related aspects were first described by mean and
standard deviation and comparison between the IH
groups (positive and negative) using Student’s t test.
Next, age was dichotomized into two groups: over and
under 40 years old. Statistical analysis was performed
with histological meningioma subtypes, astrocytoma and
glioblastoma, grouped in other histological oligoastrocy-
toma subtypes, anaplastic oligodendroglioma, anaplastic
ependymomas and unclassified glioma. Among the posi-
tive and negative IH groups, categorical data was
described by counts and percentages and comparisons
made using the Chi-square test or Fisher’s exact test in
the presence of expected values below 5. The level of
significance was 5% and the data were analyzed by
SPSS 17.0.
Abbreviations
CNS: Central nervous system; IH: Immunohistochemistry; PRL: Prolactin; PRL-R: PRL
receptor.
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